Medicine:ARCT-021
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | mrna |
| Clinical data | |
| Other names | LUNAR-COV19 |
| Routes of administration | Intramuscular |
ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.
Medical uses
It requires the intramuscular injection with a single dose.[1]
Pharmacology
ARCT-021 is an mRNA vaccine.[2]
History
Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine.[3] The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.[4]
Clinical trials
LUNAR-COV19 clinical trials in humans began in July 2020.[5] On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.[6]
Economics
Arcturus has entered into development and supply agreements with the Economic Development Board of Singapore and supply agreements with the Israel Ministry of Health for LUNAR-COV19.[7][8]
References
- ↑ "Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data". Businesswire. 10 May 2021. https://www.businesswire.com/news/home/20210510005846/en/Arcturus-Therapeutics-Announces-First-Quarter-2021-Company-Overview-and-Financial-Results-and-Provides-New-Clinical-Data.
- ↑ "Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study". Globe Newswire. 11 August 2020. https://www.globenewswire.com/news-release/2020/08/11/2076339/0/en/Arcturus-Therapeutics-Announces-that-it-has-Initiated-Dosing-of-its-COVID-19-STARR-mRNA-Vaccine-Candidate-LUNAR-COV19-ARCT-021-in-a-Phase-1-2-study.html.
- ↑ "Coronavirus: Clinical trials for Singapore's vaccine project could start in August". 15 April 2020. https://www.straitstimes.com/singapore/health/clinical-trials-for-singapores-vaccine-project-could-start-in-august.
- ↑ "With Arcturus, Catalent bags another COVID project" (in en-US). Bioprocess Insider. 6 May 2020. https://bioprocessintl.com/bioprocess-insider/facilities-capacity/with-arcturus-mrna-project-catalent-bags-another-covid-vaccine-deal/.
- ↑ Clinical trial number NCT04480957 for "Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects" at ClinicalTrials.gov
- ↑ "Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the". Bloomberg. January 4, 2021. https://www.bloomberg.com/press-releases/2021-01-04/arcturus-therapeutics-receives-fda-allowance-to-proceed-with-phase-2-study-of-arct-021-lunar-cov19-vaccine-candidate-in-the.
- ↑ "Singapore's co-developed vaccine candidate is in 'good shape' for delivery in 2021". CNBC. November 26, 2020. https://www.cnbc.com/2020/11/27/singapore-arcturus-coronavirus-vaccine-candidate-on-track-for-2021-delivery.html.
- ↑ "Singapore Will Get First Claim to Any Successful Arcturus Vaccine". Bloomberg. August 5, 2020. https://www.bloomberg.com/news/articles/2020-08-04/singapore-to-get-first-claim-to-any-successful-arcturus-vaccine.
External links
 |
